News - Abzena

Filter by year

Filter by topic

Sonnet BioTherapeutics selects Abzena as clinical stage manufacturing partner for its IL-12-FHAB cytokine-derived therapeutic candidate

PRINCETON, NJ and San Diego, CA, USA 22 October 2019 – Sonnet BioTherapeutics Inc., a clinical stage biopharmaceutical developing innovative targeted biologic drugs, announced today that it has selected Abzena as its manufacturing partner for SON-1010, an IL-12-FHAB cytokine, in preparation for clinical development. SON-1010 uses Sonnet’s proprietary FHAB™ (Fully Human Albumin Binding) technology that leverages […] Read more

Abzena Names Kimball Hall as Chief Operating Officer

Abzena announced today the appointment of Kimball Hall as Chief Operating Officer, adding to the company’s executive leadership team. Ms. Hall will focus on the growth of Abzena as the leading Partner Research Organization (PRO) for outsourced integrated gene to GMP services for large molecules and antibody drug conjugates.  She joins Abzena from Genentech, a […] Read more

Abzena offers integrated clinical translation of biologics with launch of ADC Cascade and Biologics Cascade

Cambridge, UK 07 October 2019 – Abzena, the leading biologics target to GMP Partner Research Organisation, announced it has augmented its antibody drug conjugation (ADC) and biologics (including mono and bispecific antibodies) development services with the launch of ADC Cascade and Biologics Cascade. These ex-vivo platform approaches allow efficacy and safety studies against clinically characterized […] Read more

Abzena announces successful technical transfer of Synaffix GlycoConnect™ Antibody Drug Conjugate (ADC) technology to enable use in client projects

San Diego, USA July 2019 – Abzena, the global partner research organization, announced it has successfully completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect™ (antibody conjugation) and HydraSpace™ (highly polar spacer). Familiarity with these Antibody-Drug Conjugate (ADC) technologies adds to Abzena’s leadership in process development and GMP manufacturing of ADC […] Read more

Abzena expands leadership team with Andrew Kraus as Chief Technology Officer and Philip Payne as Chief Commercial Officer

San Diego, USA , 21 June 2019 – Abzena, the leading global biologics and ADC target partner research organization, announced it has appointed Andrew Kraus as Chief Technology Officer (CTO) and Philip Payne as Chief Commercial Officer (CCO). As CTO Mr. Kraus will implement advanced technology solutions to further enhance data integrity controls, regulatory compliance […] Read more

Abzena announces 14-month cell line to phase 1 GMP service and appointment of Shahram Katousian as Head of biologics manufacturing

San Diego, USA, 3 June 2019 – Abzena, the leading biotherapeutics target to GMP partner research organization (PRO) announced an accelerated program to IND.  This reduces timeline from stable pool to GMP down to 14 months. The timeline is achieved by use of single project team with experienced leadership, overlapping of operational activities, internal technology transfer […] Read more

Abzena expands management team: appoints Campbell Bunce to the role of Chief Scientific Officer and Bo Adair as Senior Vice President Process and Operations

Cambridge, UK and San Diego, USA, 28 March 2019 – Abzena, the leading global biologics target to GMP partner research organisation, announced it has appointed Dr Campbell Bunce as Chief Scientific Officer (CSO) and Bo Adair MBA as Senior Vice President Process and Operations. Dr Bunce joined Abzena in November 2015 as SVP Scientific Operations […] Read more

Abzena Announces New Fully Integrated Developability and Optimization Service to Improve Lead Selection and De-risk Biologic Cell Line Development

Cambridge, UK 21 March 2019 – Abzena, the leading biologics target to GMP partner research organisation (PRO), announced its Cambridge UK site has brought together its extensive discovery, immunogenicity assessment, protein engineering, formulation, bioassay and analytical expertise to launch a developability assessment and optimization service to assist customers in selecting and developing the best lead candidate […] Read more

Abzena and Lipum AB sign integrated CMC agreement to produce a novel biologic for autoimmune inflammatory diseases

  San Diego, USA, 19 March 2019 – Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for […] Read more

ABZENA ANNOUNCES APPOINTMENT OF ELAINE SAPINOSO AS GLOBAL HEAD OF QUALITY

Addition of experienced leadership in GMP Quality as Abzena increases capacity in biologics and complex small molecule manufacturing San Diego, CA 4 March 2019 – Abzena today announced that it has appointed Elaine Sapinoso as Senior Vice President of Global Quality to support the addition of new manufacturing suites at 2000L scale at its San […] Read more

Interested in our services? Get In Touch